Gerrit Jessen MPI

Sunday 29th June 2008

European CEO asked Gerrit Jessen, President of Meeting Professionals International's European Council, for his views on the future of his organisation and the challenges of the industry today

Leave a comment

5 		stars5 stars5 stars5 stars5 stars
 4 stars4 stars4 stars4 stars4 stars
 3 stars3 stars3 stars3 stars3 stars
 2 stars2 stars2 stars2 stars2 stars
 1 star1 star1 star1 star1 star
Enter the words above:

Related Articles

Article tools

Special Report

A man for three seasons

Berlusconi is back for the third time, sending affectionate kisses to Italians in his victory speech and promising to revive Italy's ailing economy and slash taxes. But of course, as many Italians will tell you, they have heard it all before...

Multimedia       

Information
CEO face

Talking telepresence

We talk to Geir Olsen EMEA President of TANDBERG about improvements in telepresence technology.
CEO face

The advantages of telepresence

21st century technology: real time telepresence meetings
CEO face

Real-Time communication

Peter Quinlan explains the manifold benefits of benefits of telepresence

Bulgarian squeeze

How the EU are putting pressure on the Eastern European country.

Danone a good job

We profile Franck Riboud, CEO Danone

Artistic investment

Investing in art can yield big dividends, we investigate the market for corporate acquisitions

Open for business

How Ireland is timidly opening up to new investment strategies.

CEO Profiles

Wolfgang Mayrhuber, Lufthansa

Wolfgang Mayrhuber, Lufthansa

Lufthansa's chief has a plan for the crisis – just keep spending
Eric Schmidt, Google

Eric Schmidt, Google

Eric Schmidt, the current CEO of Google, also works for Apple. You'd think that being part of one globe-conquering corporation would be enough for one man, but you'd be wrong
Severin Schwan, Roche

Severin Schwan, Roche

Rejuvenated Roche has revealed record sales in the teeth of a recession. Its young 42-year-old CEO Severin Schwan has also masterminded its $47m takeover of biotech star Genentech. Schwan is investing in science, not short-term sales. Will it work?